TEVA PHARMACEUTICAL-SP ADR (TEVA)

US8816242098 - ADR

14.11  -0.32 (-2.22%)

After market: 14.11 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

TEVA PHARMACEUTICAL-SP ADR

NYSE:TEVA (3/28/2024, 8:04:00 PM)

After market: 14.11 0 (0%)

14.11

-0.32 (-2.22%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap15.82B
Shares
PE5.51
Fwd PE5.83
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

TEVA Daily chart

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Company Info

TEVA PHARMACEUTICAL-SP ADR

5 Bazel St, P O B 3190

Petah Tikva 49131

P: 97239267267

CEO: Kare Schultz

Employees: 34004

Website: https://www.tevapharm.com/

TEVA News

News Imagea month ago - Seeking AlphaUroGen stock falls as Teva seeks Jelmyto generic (NASDAQ:URGN)

Shares of UroGen Pharma (URGN) fell after Teva Pharma (TEVA) filed for FDA approval of a generic version of URGN's bladder cancer therapy, Jelmyto. Read more here.

News Imagea month ago - Market News VideoApril 12th Options Now Available For Teva Pharmaceutical Industries
News Imagea month ago - Investor's Business DailyDrug Maker Organon Stock Scores Relative Strength Upgrade

In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.

News Imagea month ago - InvestorPlaceEthereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000?

Ethereum price predictions are a hot topic on Monday as crypto traders wonder where the token will go after surpassing $3,000.

News Imagea month ago - InvestorPlaceJefferies Just Raised Its Price Target on Salesforce (CRM) Stock

Salesforce stock is rising higher on Monday after CRM shares got an increased price target from Jefferies analysts this morning.

News Imagea month ago - InvestorPlaceTEVA Stock Pops 4% as Teva Receives FDA Approval

Teva Pharmaceutical stock is rising higher on Monday after partner company Alvotech got approval from the FDA for a Humira biosimilar.

TEVA Twits

Here you can normally see the latest stock twits on TEVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example